Mass spectrometry-based proteomic analysis of formalin-fixed paraffin-embedded extrahepatic cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 9, 2015, Pages 683-691

  Maeda, Shimpei ^a,b   Morikawa, Takanori ^a   Takadate, Tatsuyuki ^a   Suzuki, Takashi ^a   Minowa, Takashi ^c   Hanagata, Nobutaka ^c   Onogawa, Tohru ^a   Motoi, Fuyuhiko ^a   Nishimura, Toshihide ^d   Unno, Michiaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b South Miyagi Medical Center   (Japan)

^c NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Extrahepatic cholangiocarcinoma; Mass spectrometry; Proteomics; Scheduled selected reaction monitoring

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CADHERIN; CARBAMOYL PHOSPHATE SYNTHASE; FATTY ACID BINDING PROTEIN; KERATIN; MUCIN 5AC; ORNITHINE OXOACID AMINOTRANSFERASE; PROTEIN CAD17; PROTEIN CEAM5; PROTEIN FABPL; PROTEIN K1C20; PROTEIN OLFM4; PROTEIN S 100; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; EXTRAHEPATIC CHOLANGIOCARCINOMAA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SELECTED REACTION MONITORING; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; BILE DUCT TUMOR; CHEMISTRY; COMPARATIVE STUDY; EXTRAHEPATIC BILE DUCT; MIDDLE AGED; PATHOLOGY; PROCEDURES; TISSUE FIXATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEOMICS; RETROSPECTIVE STUDIES; TISSUE FIXATION; YOUNG ADULT;

EID: 84939572998     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.262     Document Type: Article

References (47)

1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD,. Cholangiocarcinoma. Lancet. 2005; 366: 1303-14.
2. Shaib Y, El-Serag HB,. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004; 24: 115-25.
3. Ishihara S, Miyakawa S, Takada T, Takasaki K, Nimura Y, Tanaka M, et al., Status of surgical treatment of biliary tract cancer. Dig Surg. 2007; 24: 131-6.
4. Pandey A, Mann M,. Proteomics to study genes and genomes. Nature. 2000; 405: 837-46.
5. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359: 572-7.
6. Washburn MP, Wolters D, Yates JR III,. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol. 2001; 19: 242-7.
7. Anderson L, Hunter CL,. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2006; 5: 573-88.
8. Anderson NL, Anderson NG,. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1: 845-67.
9. Prieto DA, Hood BL, Darfler MM, Guiel TG, Lucas DA, Conrads TP, et al., Liquid Tissue: proteomic profiling of formalin-fixed tissues. Biotechniques. 2005; 38: 32-5.
10. Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, et al., Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics. 2005; 4: 1741-53.
11. Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, et al., Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer. 2013; 132: 1368-82.
12. Kawamura T, Nomura M, Tojo H, Fujii K, Hamasaki H, Mikami S, et al., Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. J Proteomics. 2010; 73: 1089-99.
13. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al., Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics. 2005; 4: 1487-502.
14. Zybailov B, Coleman MK, Florens L, Washburn MP,. Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. Anal Chem. 2005; 77: 6218-24.
15. Sokal RR, Rohlf FJ,. Biometry: the principles and practice of statistics in biological research, 3rd edn. New York: W. H. Freeman and Company; 1995.
16. Alvaro D,. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009; 25: 279-84.
17. Bonney GK, Craven RA, Prasad R, Melcher AF, Selby PJ, Banks RE,. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 2008; 9: 149-58.
18. Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, et al., Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues. J Proteome Res. 2009; 8: 4092-103.
19. Wang X, Dai S, Zhang Z, Liu L, Wang J, Xiao X, et al., Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care. 2009; 18: 625-35.
20. Nishimura T, Nomura M, Tojo H, Hamasaki H, Fukuda T, Fujii K, et al., Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. J Proteomics. 2010; 73: 1100-10.
21. Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE,. Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics. 2005; 5: 566-71.
22. Aishima S, Fujita N, Mano Y, Kubo Y, Tanaka Y, Taketomi A, et al., Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol. 2011; 35: 590-8.
23. Nakanishi Y, Zen Y, Kawakami H, Kubota K, Itoh T, Hirano S, et al., Extrahepatic bile duct carcinoma with extensive intraepithelial spread: a clinicopathological study of 21 cases. Mod Pathol. 2008; 21: 807-16.
24. Takamura M, Yamagiwa S, Wakai T, Tamura Y, Kamimura H, Kato T, et al., Loss of liver-intestine cadherin in human intrahepatic cholangiocarcinoma promotes angiogenesis by up-regulating metal-responsive transcription factor-1 and placental growth factor. Int J Oncol. 2010; 36: 245-54.
25. Hodorova I, Rybarova S, Vecanova J, Solar P, Domorakova I, Adamkov M, et al., Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma. Med Sci Monit. 2012; 18: BR482-6.
26. Shimonishi T, Miyazaki K, Nakanuma Y,. Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver. Histopathology. 2000; 37: 55-63.
27. Hashimoto T, Kusakabe T, Watanabe K, Sugino T, Fukuda T, Nashimoto A, et al., Liver-type fatty acid-binding protein is highly expressed in intestinal metaplasia and in a subset of carcinomas of the stomach without association with the fatty acid synthase status in the carcinoma. Pathobiology. 2004; 71: 115-22.
28. Kobayashi D, Koshida S, Moriai R, Tsuji N, Watanabe N,. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci. 2007; 98: 334-40.
29. Liu W, Chen L, Zhu J, Rodgers GP,. The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res. 2006; 312: 1785-97.
30. Liu W, Zhu J, Cao L, Rodgers GP,. Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology. 2007; 51: 157-65.
31. Miyasaka Y, Enomoto N, Nagayama K, Izumi N, Marumo F, Watanabe M, et al., Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. Br J Cancer. 2001; 85: 228-34.
32. Lee HJ, Nam KT, Park HS, Kim MA, Lafleur BJ, Aburatani H, et al., Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. Gastroenterology. 2010; 139: 213-25. e3.
33. Lawrie LC, Dundas SR, Curran S, Murray GI,. Liver fatty acid binding protein expression in colorectal neoplasia. Br J Cancer. 2004; 90: 1955-60.
34. Sharaf RN, Butte AJ, Montgomery KD, Pai R, Dudley JT, Pasricha PJ,. Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes. BMC Gastroenterol. 2011; 11: 5.
35. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, et al., A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A. 2006; 103: 10991-6.
36. Liu TH, Li DC, Gu CF, Ye SF,. Carbamyl phosphate synthetase I. A novel marker for gastric carcinoma. Chin Med J (Engl). 1989; 102: 630-8.
37. Kinoshita M, Miyata M,. Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology. 2002; 36: 433-8.
38. Hamada S, Satoh K, Hirota M, Kanno A, Ishida K, Umino J, et al., Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci. 2011; 102: 150-6.
39. Minato H, Nakanuma Y, Terada T,. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts. Histopathology. 1996; 28: 411-9.
40. Boonla C, Wongkham S, Sheehan JK, Wongkham C, Bhudhisawasdi V, Tepsiri N, et al., Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer. 2003; 98: 1438-43.
41. Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P,. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 2000; 24: 870-6.
42. Lankisch TO, Metzger J, Negm AA, Vobetakuhl K, Schiffer E, Siwy J, et al., Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology. 2011; 53: 875-84.
43. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al., Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5: 1221-8.
44. Fillatre Y, Rondeau D, Jadas-Hecart A, Communal PY,. Advantages of the scheduled selected reaction monitoring algorithm in liquid chromatography/electrospray ionization tandem mass spectrometry multi-residue analysis of 242 pesticides: a comparative approach with classical selected reaction monitoring mode. Rapid Commun Mass Spectrom. 2010; 24: 2453-61.
45. Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, et al., Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 2009; 125: 2383-92.
46. Lachmann RA, Werchan S, Schachtrup C, Haitsma JJ, Spener F, Lachmann B,. Liver-type fatty acid binding protein in serum and broncho-alveolar lavage in a model of acute respiratory failure because of surfactant depletion - a possible marker for lung damage? Clin Physiol Funct Imaging. 2006; 26: 371-5.
47. Wang Q, Zhang YN, Lin GL, Qiu HZ, Wu B, Wu HY, et al., S100P, a potential novel prognostic marker in colorectal cancer. Oncol Rep. 2012; 28: 303-10.